An FDA advisory panel voted 8-6 to recommend compounding the peptides BPC-157 and KPV. The vote is non-binding and the peptides are not FDA-approved.
An FDA advisory panel voted 8 to 6 on July 23, 2026, to recommend adding the peptides BPC-157 and KPV to the 503A compounding bulks list. The vote, which also backed TB-500 and MOTS-c, is non-binding. None of these peptides are FDA-approved, and agency scientists opposed the move.
An FDA advisory committee narrowly recommended letting compounding pharmacies prepare two contested peptides, BPC-157 and KPV, in a vote that split the panel and overrode the agency's own scientists. The Pharmacy Compounding Advisory Committee voted 8 to 6, with one abstention, on July 23, 2026, and also backed TB-500 and MOTS-c. The recommendation is non-binding, and none of these peptides are FDA-approved for any use.
The vote matters because it is a step, not a decision. A favorable committee recommendation does not change what pharmacies can legally compound today. The FDA still has to accept the advice and complete a formal rulemaking process that can take a year or more, and the agency retains the final say.
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted 8 to 6, with one abstention, to recommend adding BPC-157 and KPV to the 503A Bulks List. That list names substances state-licensed compounding pharmacies may prepare for individual patients without an FDA-approved product or a USP monograph. The committee also voted to back TB-500 and MOTS-c during the same session, with additional peptides scheduled for review the next day.
In the discussion, BPC-157 was framed as a candidate for ulcerative colitis and KPV for wound treatment and inflammatory conditions. None of these peptides are FDA-approved. They currently sit under FDA restrictions that keep compounders from using them, which is exactly what the committee vote sought to change.
The recommendation is notable because it went against FDA staff scientists, who urged the committee not to add the peptides. Agency reviewers cited a lack of evidence that BPC-157 works for ulcerative colitis, said the substances are not well-characterized, and warned that quality standards cannot be established. Reviewers also noted a small number of adverse event reports following BPC-157 injection, though causality was not established. Evidence for these peptides remains limited.
The split vote and the abstention underscore how contested the science is. One skeptical panelist said there were too many unknowns about the product, while a supportive member argued the choice belonged with physicians and pharmacists. Reporting also noted that several panelists who voted yes have ties to the peptide industry, a conflict worth weighing when reading the outcome.
Nothing changes for patients or clinics right now. PCAC recommendations are advisory, and the FDA will decide whether to lift the current restrictions. Even a yes triggers formal notice-and-comment rulemaking that can run 12 months or more before any of these peptides could be legally compounded under 503A. Historically the FDA rarely rejects PCAC advice, but it has done so before.
Until the FDA finalizes a rule, BPC-157, KPV, TB-500, and MOTS-c stay off-limits for lawful compounding and remain not FDA-approved. Anyone weighing these products should treat marketing claims cautiously, since the underlying evidence is thin and the regulatory status is unsettled. This story sits in the peptide and longevity lane that injector.world tracks as Phase 2, distinct from approved aesthetic injectables.